A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease
This research study is testing a new daily medicine, etavopivat, for children and teenagers with sickle cell disease. We want to understand how safe it is and how it works in the body. We'll also be looking to see if it has any benefits for those taking it. Participants will take the medicine for 96 weeks, which is about 1 year and 10 months. During this time, they will have regular check-ups. The study aims to gather important information to help us understand if etavopivat could be a new treatment option for sickle cell disease.
De un vistazo
¿De qué trata este estudio?
Sickle cell disease is a lifelong condition that affects red blood cells. These cells, which are usually round and flexible, become stiff and C-shaped, like a sickle. This can block blood flow, causing pain, tiredness, and other serious health problems. It's a condition that can have a big impact on daily life, especially for young people.
This study, called "A Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell Disease," is looking at a new medicine called etavopivat. This medicine is designed to be taken once a day by mouth. The main goal is to understand if etavopivat is safe for children and teenagers with sickle cell disease and how their bodies handle the medicine, including how long it stays in their system.
Doctors are also interested in finding out if taking etavopivat can offer any improvements for people with sickle cell disease. By carefully studying this medicine, researchers hope to learn if it could become a helpful new treatment in the future. This is a "Phase 2" study, which means it's one of the earlier stages of testing a new medicine in people.
Puntos clave
- This study is for children and teenagers with sickle cell disease.
- It's testing a new daily medicine called etavopivat.
- The main goals are to check the medicine's safety and how it works in the body.
- Participation involves taking medicine daily for about 1 year and 10 months, with regular check-ups.
- The study aims to see if etavopivat could be a new treatment option for sickle cell disease in the future.
¿Quién puede ser elegible?
This study is looking for children and teenagers with sickle cell disease. Participants must be between 6 months and 18 years old when they join the study. If you're under 18, your parent or guardian will need to give their permission for you to take part, and you'll also need to agree if you're old enough.
To be considered, you need to have a confirmed diagnosis of sickle cell disease, which can be shown by previous blood tests. Your haemoglobin level (a measure of red blood cells) also needs to be within a certain range. The study is specifically for those with more severe sickle cell disease, meaning you've had certain health issues related to your condition in the past year, such as several pain crises or hospital stays. Your doctor will be able to check all these details to see if you might be a good fit.
¿Podría este estudio ser adecuado para ti?
Responde estas preguntas rápidas para ver si puedes ser elegible. Esto es solo una guía: el equipo de investigación toma la decisión final.
- Are you between 6 months and 18 years old?
- Do you have a diagnosis of sickle cell disease?
- Has your sickle cell disease caused you to have certain serious health problems in the past year (like several pain crises or hospital stays)?
- Is your haemoglobin level within the required range (between 5.5 and 10.5 g/dL)?
- Are your parents or guardians willing to give permission for you to join?
¿En qué consiste la participación?
If you join this study, you'll be taking the study medicine, etavopivat, once a day by mouth for 96 weeks (that's about 1 year and 10 months). During this time, you'll have regular visits to the clinic so the study team can check on your health and how you're responding to the medicine. These visits will likely include physical exams, blood tests, and discussions about how you're feeling. After the 96-week treatment period, there will be one final check-up about a month later to make sure everything is okay.
Riesgos y beneficios potenciales
Locations (18)
- El Hospital para Niños EnfermosCódigo postal verificadoToronto, Canadá· Completado
- HCL-HOPITAL LYON SUD_Institut d'Hématologie et d'Oncologie Pédiatrique (IHOPe)Código postal verificadoLyon, Francia· Aún no reclutando
- APHP - Centre de Référence des SyndromesCódigo postal verificadoParís, Francia· Aún no reclutando
- Centre Hospitalier Universitaire de Rouen-Hopital Charles NicolleNo verificadoRoeun, France· Aún no reclutando
- KEMRI CRDR Siaya Clinical Research Annex, Country Referral HospitalCódigo postal verificadoSiaya, Kenya· Reclutamiento
- KEMRI-Walter-Reed KerichoCódigo postal verificadoKericho, Kenya· Reclutamiento
- Kombewa Clinical Research CentreCódigo postal verificadoKisumu, Kenya· Reclutamiento
- Ahero Clinical Trials UnitCódigo postal verificadoKisumu, Kenya· Reclutamiento
- American University of Beirut Medical centerCódigo postal verificadoBeirut, Lebanon· Reclutamiento
- Hospital NiniCódigo postal verificadoTripoli, Lebanon· Reclutamiento
- University of Nigeria Teaching Hospital (UNTH)No verificadoItuku-Ozalla, Nigeria· Reclutamiento
- Lagos University Teaching Hospital, LagosCódigo postal verificadoLagos, Nigeria· Reclutamiento
Preguntas comunes
What is sickle cell disease?
Sickle cell disease is a genetic condition where red blood cells become stiff and C-shaped, which can block blood flow and cause pain and other health problems.
What is etavopivat?
Etavopivat is a new medicine being tested in this study. It's a tablet taken once a day by mouth for people with sickle cell disease.
¿Cuánto dura el estudio?
If you join, you will be taking the medicine for 96 weeks (about 1 year and 10 months), followed by a final check-up about 4 weeks later.
¿Quién puede participar en este estudio?
The study is for children and teenagers with confirmed sickle cell disease, aged between 6 months and 18 years, who meet specific health criteria.
What do they hope to learn from this study?
Researchers want to learn if etavopivat is safe, how it works in the body, and if it can help improve the health of people with sickle cell disease.
Cómo obtener más información
Novo Nordisk
Siempre hable con su médico de cabecera o especialista antes de decidir participar en un estudio.
¿Interesado en participar?
Discusión
Discusión comunitaria
Impulsado por nuestro foro en community.patient.info. Por favor, sea respetuoso — esto no es un consejo médico.